Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.53 |
| ▸ | THRA | P10827 | 1/20 | 0.50 |
| ▸ | RARB | P10826 | 1/20 | 0.49 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4447937 | 0.98 | MAPT (0.54) | MAPTTHRARARBCTNNB1RAB9A | |
| SCHEMBL7404631 | 0.87 | MAPT (0.53) | MAPTTHRARARBCTNNB1RAB9A | |
| SCHEMBL2855827 | 0.85 | MAPT (0.58) | MAPTTHRARARBRAB9AL3MBTL1 | |
| SCHEMBL20574599 | 0.85 | MAPT (0.58) | MAPTTHRARARBRAB9AL3MBTL1 | |
| SCHEMBL841978 | 0.83 | ESR2 (0.50) | MAPTRAB9ANPC1L3MBTL1ALDH1A1 | |
| SCHEMBL13448825 | 0.83 | RARB (0.68) | MAPTRARBRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL15562010 | 0.83 | RARB (0.68) | MAPTRARBRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL13894709 | 0.83 | L3MBTL1 (0.68) | MAPTRARBRAB9AL3MBTL1ALDH1A1 | |
| SCHEMBL9019628 | 0.83 | RARB (0.68) | MAPTRARBRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL4445351 | 0.83 | L3MBTL1 (0.68) | MAPTRARBRAB9AL3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7572938-B2 | Precursors for ketones and aldehydes | GIVAUDAN SA (CH) | 2009-08-11 | — | — | US | disclosed |
| US-20040171516-A1 | Precursors for ketones and aldehydes | GIVAUDAN SA (CH) | 2004-09-02 | — | — | US | disclosed |
| EP-1262473-A1 | Precursors for fragrant ketones and fragrant aldehydes | Givaudan SA (CH) | 2002-12-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171516-A1 | Precursors for ketones and aldehydes | PDK3, PDK4, AKR1C4 | MAPT 3633/4885THRA 4624/4885RARB 2697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.